Form 4: Kymera CMO Jared Gollob Receives Equity, Sells Shares for Tax

Kymera Therapeutics' Chief Medical Officer, Jared Gollob, was granted 17,650 restricted stock units and 35,300 stock options, while also selling 10,508 shares to cover tax obligations.

Summary

• Jared Gollob, Chief Medical Officer of Kymera Therapeutics, Inc. (KYMR), acquired 17,650 restricted stock units (RSUs) on March 2, 2026.
• These RSUs represent a contingent right to receive one share of common stock upon vesting and will vest in four equal annual installments following March 2, 2026, contingent on continued employment.
• Gollob also acquired 35,300 stock options on March 2, 2026, with an exercise price of $90.1 per share.
• These stock options will vest in forty-eight equal monthly installments following March 2, 2026, subject to continued employment, and expire on March 1, 2036.
• On March 2, 2026, Gollob sold a total of 5,613 shares of common stock at weighted average prices ranging from $87.7509 to $89.6574.
• On March 4, 2026, Gollob sold an additional 4,895 shares of common stock at weighted average prices ranging from $83.9965 to $86.6247.
• These sales, totaling 10,508 shares, were automatic transactions to cover tax withholding obligations associated with the vesting of RSUs and were not discretionary.
• Following these transactions, Gollob beneficially owns 117,134 shares of common stock and 35,300 stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a routine insider transaction reflecting ongoing executive compensation and tax management. The grants are positive for executive alignment, while the sales are non-discretionary tax events.

Positives

• Grant of 17,650 Restricted Stock Units (RSUs) to the Chief Medical Officer, aligning executive incentives with shareholder value.
• Grant of 35,300 stock options with an exercise price of $90.1, providing long-term incentive for the Chief Medical Officer.
• The equity grants demonstrate continued commitment to executive compensation and retention.

Negatives

• Sales of 10,508 shares of common stock by the Chief Medical Officer, even if for tax purposes, represent a reduction in direct ownership.

Future Outlook

The RSUs will vest in four equal annual installments following March 2, 2026, subject to continued employment. The stock options will vest in forty-eight equal monthly installments following March 2, 2026, subject to continued employment, and expire on March 1, 2036.

Industry Context

StockSavvy.ai notes that equity grants, including restricted stock units and stock options, are standard practice in the biotechnology and pharmaceutical industries for executive compensation. These grants are designed to align the interests of executives with long-term shareholder value creation, a common strategy among peers like Moderna (MRNA) or BioNTech (BNTX) in retaining key scientific and medical talent. The tax-related sales are also a routine occurrence when equity awards vest.

Comparison to Industry Standards

• Equity compensation packages, including RSUs and stock options, are a common component of executive remuneration across the biotech sector, comparable to practices at companies such as Vertex Pharmaceuticals (VRTX) or Regeneron Pharmaceuticals (REGN).
• The vesting schedules (four-year annual for RSUs, four-year monthly for options) are typical for incentivizing long-term executive retention and performance.
• Tax-related sales upon RSU vesting are a standard mechanism for executives to meet tax obligations without needing to use personal funds, a practice observed widely across publicly traded companies.

Stakeholder Impact

• Shareholders: The equity grants align the Chief Medical Officer's interests with long-term shareholder value. The tax-related sales are minor in the context of total shares outstanding and are not indicative of a lack of confidence.
• Employees: Reflects standard executive compensation practices, which can influence overall compensation philosophy.

Next Steps

• The RSUs will vest in four equal annual installments following March 2, 2026.
• The stock options will vest in forty-eight equal monthly installments following March 2, 2026.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation grants and subsequent non-discretionary tax-related sales by a key executive. Such transactions are standard and do not typically signal a change in company fundamentals or management's outlook. The grants are a positive for executive alignment, while the sales are a mechanical consequence of vesting. Therefore, the filing itself does not provide a basis for a "buy" or "sell" recommendation, suggesting a "hold" position based solely on this information.

Keywords

Kymera Therapeutics, KYMR, Jared Gollob, Chief Medical Officer, Form 4, Insider Trading, Restricted Stock Units, Stock Options, Equity Compensation, Tax Withholding, Share Sales